|
시장보고서
상품코드
1762319
세계의 성병 분자진단 시장, 규모, 점유율, 동향, 산업 분석 보고서 : 제품별, 용도별, 기술별, 지역별, 예측(2025-2034년)Molecular Diagnostics For Sexually Transmitted Diseases Market Size, Share, Trends, & Industry Analysis Report By Product (Instruments & Services, Consumables, and Software), By Application, By Technology, By Region - Market Forecast, 2025-2034 |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
Polaris Market Research의 최신 조사에 따르면, 성병 분자진단 세계 시장 규모는 2034년까지 78억 5,000만 달러에 달할 것으로 예측됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 통찰력과 미래 시장 성장에 대한 분석을 제공합니다.
성병(STD) 분자진단은 성병을 일으키는 미생물의 DNA, RNA 등 유전물질을 확인하는 고도의 실험 기술을 포함하고 있습니다. 항체나 배양액을 검사하는 기존 방식과 달리 분자검사는 병원체 자체를 직접 확인합니다. 이를 통해 정확하고 민감한 검출이 가능해져 감염 초기 단계나 증상이 아직 나타나지 않은 단계에서도 진단이 가능한 경우가 많습니다.
성병 분자진단 시장은 전 세계적으로 성병 유병률 증가로 인해 크게 성장하고 있으며, 공중보건 문제를 관리하기 위해 보다 효과적이고 신속한 진단 솔루션이 요구되고 있습니다. 또한, 여러 병원체를 동시에 검출할 수 있는 멀티플렉스 분석법 개발 등 분자 검사의 지속적인 기술 발전으로 검사 효율성과 접근성이 향상되고 있습니다. 성병의 조기 및 정확한 진단의 중요성에 대한 의료 전문가와 일반인의 인식이 높아진 것도 이러한 첨단 진단법의 채택 확대에 기여하고 있습니다.
성병 분자진단 시장 보고서 하이라이트
제품별로는 시약 및 키트를 포함한 소모품 분야가 모든 분자 성병 검사에서 중요한 역할을 하기 때문에 가장 큰 점유율을 차지하고 있습니다.
용도별로는 CT/NG 검사 분야가 2024년에 지배적이었습니다.
기술 측면에서는 중앙 집중식 실험실의 확립된 인프라에 힘입어 실험실 검사 부문이 2024년 가장 큰 점유율을 차지했습니다.
지역별로는 북미가 2024년 성병 분자진단 시장 매출 점유율을 차지했습니다. 아시아태평양은 예측 기간 동안 가장 빠르게 성장할 것으로 예측됩니다.
이 시장의 주요 기업으로는 Abbott Laboratories, F. Hoffmann-La Roche AG(Roche Diagnostics), bioMerieux SA, QIAGEN N.V., Hologic Inc. Company（BD）,Siemens Healthineers AG,DiaSorin S.p.A.,Thermo Fisher Scientific Inc. 등이 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 성병 분자진단 시장 분석
- 시장 현황
- 성병 분자진단 시장 역학
- 성장 촉진요인과 기회
- 성장 억제요인과 과제
- PESTEL 분석
- 성병 분자진단 시장 용도 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 성병 분자진단 시장 : 제품별
- 주요 조사 결과
- 서론
- 기기 및 서비스
- 소모품
- 소프트웨어
제6장 성병 분자진단 시장 : 용도별
- 주요 조사 결과
- 서론
- CT/NG 검사
- 매독 검사
- 임질 검사
- HSV 검사
- HPV 검사
- HIV 검사
- 트리코모나스
- 우레아 플라즈마+ 마이코플라즈마
- 기타
제7장 성병 분자진단 세계 시장 : 기술별
- 주요 조사 결과
- 서론
- 임상 검사
- PoC 테스트
제8장 성병 분자진단 시장 : 지역별
- 주요 조사 결과
- 서론
- 성병 분자진단 시장 평가 : 지역별, 2020-2034년
- 북미
- 북미 : 제품별, 2020-2034년
- 북미 : 용도별, 2020-2034년
- 북미 : 기술별, 2020-2034년
- 미국
- 캐나다
- 유럽
- 유럽 : 제품별, 2020-2034년
- 유럽 : 용도별, 2020-2034년
- 유럽 : 기술별, 2020-2034년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 제품별, 2020-2034년
- 아시아태평양 : 용도별, 2020-2034년
- 아시아태평양 : 기술별, 2020-2034년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 제품별, 2020-2034년
- 중동 및 아프리카 : 용도별, 2020-2034년
- 중동 및 아프리카 : 기술별, 2020-2034년
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 제품별, 2020-2034년
- 라틴아메리카 : 용도별, 2020-2034년
- 라틴아메리카 : 기술별, 2020-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제9장 경쟁 구도
- 확대와 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제10장 기업 개요
- Abbott Laboratories
- Becton, Dickinson and Company(BD)
- bioMerieux SA
- DiaSorin S.p. A.
- F. Hoffmann-La Roche AG(Roche Diagnostics)
- Hologic Inc.
- QIAGEN N.V.
- QuidelOrtho Corporation
- Seegene Inc.
- Siemens Healthineers AG
- Thermo Fisher Scientific Inc.
The global molecular diagnostics for sexually transmitted diseases market size is expected to reach USD 7.85 billion by 2034, according to a new study by Polaris Market Research. The report "Molecular Diagnostics for Sexually Transmitted Diseases Market Size, Share, Trends, & Industry Analysis Report By Product (Instruments & Services, Consumables, and Software), By Application, By Technology, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Molecular diagnostics for sexually transmitted diseases (STDs) involves advanced laboratory techniques that pinpoint the genetic material, such as DNA or RNA, of the microorganisms causing these infections. Unlike older methods that might look for antibodies or grown cultures, molecular tests directly identify the pathogen itself. This allows for highly accurate and sensitive detection, often enabling diagnosis even in the early stages of an infection or when symptoms are not yet present, which is crucial for timely treatment and preventing further spread.
The market for molecular diagnostics for STDs is experiencing significant growth due to the rising global incidence of STDs, which necessitates more effective and rapid diagnostic solutions to manage public health challenges. Additionally, ongoing technological advancements in molecular testing, including the development of multiplex assays that can detect multiple pathogens simultaneously, are enhancing testing efficiency and accessibility. The increasing awareness among healthcare professionals and the general public about the importance of early and accurate STD diagnosis also contributes to the expanding adoption of these advanced diagnostic methods.
Molecular Diagnostics for Sexually Transmitted Diseases Market Report Highlights:
By product, the consumables segment, encompassing reagents and kits, holds the largest share due to its essential role in every molecular STD test.
Based on application, the CT/NG testing segment dominated in 2024 as these are among the most prevalent STDs worldwide.
In terms of technology, the laboratory testing segment held the largest share in 2024, supported by the established infrastructure of centralized labs.
By region, North America dominated the molecular diagnostics for sexually transmitted diseases market revenue share in 2024. Asia Pacific is projected to witness the fastest growth during the forecast period.
A few key players in the market include Abbott Laboratories; F. Hoffmann-La Roche AG (Roche Diagnostics); bioMerieux SA; QIAGEN N.V.; Hologic Inc.; Becton, Dickinson and Company (BD); Siemens Healthineers AG; DiaSorin S.p.A.; Thermo Fisher Scientific Inc.; QuidelOrtho Corporation; and Seegene Inc.
Polaris Market Research has segmented the molecular diagnostics for sexually transmitted diseases market report on the basis of product, application, technology, and region:
By Product Outlook (Revenue - USD Billion, 2020-2034)
Instruments & Services
Consumables
Software
By Application Outlook (Revenue - USD Billion, 2020-2034)
CT/NG Testing
Syphilis Testing
Gonorrhea Testing
HSV Testing
HPV Testing
HIV Testing
Trichomonas
Ureaplasma + Mycoplasma
Others
By Technology Outlook (Revenue - USD Billion, 2020-2034)
Laboratory Testing
Commercial/Private Labs
Public Health Labs
PoC testing
By Regional Outlook (Revenue - USD Billion, 2020-2034)
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Source
- 3.2.1. Primary Source
- 3.2.2. Secondary Source
4. Global Molecular Diagnostics For Sexually Transmitted Diseases Market Insights
- 4.1. Molecular Diagnostics For Sexually Transmitted Diseases Market - Market Snapshot
- 4.2. Molecular Diagnostics For Sexually Transmitted Diseases Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing Incidence of Sexually Transmitted Diseases
- 4.2.1.2. Technological Advancements in Diagnostic Tools
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High Cost of Diagnostic Tests and Equipment
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Molecular Diagnostics For Sexually Transmitted Diseases Market Application Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 5.3. Instruments & Services
- 5.3.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Instruments & Services, by Region, 2020-2034 (USD Billion)
- 5.4. Consumables
- 5.4.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Consumables, by Region, 2020-2034 (USD Billion)
- 5.5. Software
- 5.5.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Software, by Region, 2020-2034 (USD Billion)
6. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 6.3. CT/NG testing
- 6.3.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by CT/NG testing, by Region, 2020-2034 (USD Billion)
- 6.4. Syphilis testing
- 6.4.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Syphilis testing, by Region, 2020-2034 (USD Billion)
- 6.5. Gonorrhea testing
- 6.5.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Gonorrhea testing, by Region, 2020-2034 (USD Billion)
- 6.6. HSV testing
- 6.6.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by HSV testing, by Region, 2020-2034 (USD Billion)
- 6.7. HPV testing
- 6.7.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by HPV testing, by Region, 2020-2034 (USD Billion)
- 6.8. HIV testing
- 6.8.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by HIV testing, by Region, 2020-2034 (USD Billion)
- 6.9. Trichomonas
- 6.9.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Trichomonas, by Region, 2020-2034 (USD Billion)
- 6.10. Ureaplasma + Mycoplasma
- 6.10.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Ureaplasma + Mycoplasma, by Region, 2020-2034 (USD Billion)
- 6.11. Others
- 6.11.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Others, by Region, 2020-2034 (USD Billion)
7. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 7.3. Laboratory Testing
- 7.3.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Laboratory Testing, by Region, 2020-2034 (USD Billion)
- 7.3.2. Commercial/Private Labs
- 7.3.3. Public Health Labs
- 7.4. PoC testing
- 7.4.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by PoC testing, by Region, 2020-2034 (USD Billion)
8. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Geography
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Molecular Diagnostics For Sexually Transmitted Diseases Market Assessment, By Geography, 2020-2034 (USD Billion)
- 8.3. Molecular Diagnostics For Sexually Transmitted Diseases Market - North America
- 8.3.1. North America: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.3.2. North America: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.3.3. North America: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.3.4. Molecular Diagnostics For Sexually Transmitted Diseases Market - U.S.
- 8.3.4.1. U.S.: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.3.4.2. U.S.: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.3.4.3. U.S.: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.3.5. Molecular Diagnostics For Sexually Transmitted Diseases Market - Canada
- 8.3.5.1. Canada: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.3.5.2. Canada: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.3.5.3. Canada: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.4. Molecular Diagnostics For Sexually Transmitted Diseases Market - Europe
- 8.4.1. Europe: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.4.2. Europe: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.4.3. Europe: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.4.4. Molecular Diagnostics For Sexually Transmitted Diseases Market - UK
- 8.4.4.1. UK: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.4.4.2. UK: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.4.4.3. UK: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.4.5. Molecular Diagnostics For Sexually Transmitted Diseases Market - France
- 8.4.5.1. France: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.4.5.2. France: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.4.5.3. France: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.4.6. Molecular Diagnostics For Sexually Transmitted Diseases Market - Germany
- 8.4.6.1. Germany: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.4.6.2. Germany: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.4.6.3. Germany: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.4.7. Molecular Diagnostics For Sexually Transmitted Diseases Market - Italy
- 8.4.7.1. Italy: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.4.7.2. Italy: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.4.7.3. Italy: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.4.8. Molecular Diagnostics For Sexually Transmitted Diseases Market - Spain
- 8.4.8.1. Spain: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.4.8.2. Spain: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.4.8.3. Spain: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.4.9. Molecular Diagnostics For Sexually Transmitted Diseases Market - Netherlands
- 8.4.9.1. Netherlands: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.4.9.2. Netherlands: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.4.9.3. Netherlands: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.4.10. Molecular Diagnostics For Sexually Transmitted Diseases Market - Russia
- 8.4.10.1. Russia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.4.10.2. Russia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.4.10.3. Russia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.4.11. Molecular Diagnostics For Sexually Transmitted Diseases Market - Rest of Europe
- 8.4.11.1. Rest of Europe: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.4.11.2. Rest of Europe: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.4.11.3. Rest of Europe: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.5. Molecular Diagnostics For Sexually Transmitted Diseases Market - Asia Pacific
- 8.5.1. Asia Pacific: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.5.2. Asia Pacific: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.5.3. Asia Pacific: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.5.4. Molecular Diagnostics For Sexually Transmitted Diseases Market - China
- 8.5.4.1. China: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.5.4.2. China: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.5.4.3. China: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.5.5. Molecular Diagnostics For Sexually Transmitted Diseases Market - India
- 8.5.5.1. India: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.5.5.2. India: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.5.5.3. India: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.5.6. Molecular Diagnostics For Sexually Transmitted Diseases Market - Malaysia
- 8.5.6.1. Malaysia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.5.6.2. Malaysia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.5.6.3. Malaysia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.5.7. Molecular Diagnostics For Sexually Transmitted Diseases Market - Japan
- 8.5.7.1. Japan: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.5.7.2. Japan: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.5.7.3. Japan: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.5.8. Molecular Diagnostics For Sexually Transmitted Diseases Market - Indonesia
- 8.5.8.1. Indonesia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.5.8.2. Indonesia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.5.8.3. Indonesia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.5.9. Molecular Diagnostics For Sexually Transmitted Diseases Market - South Korea
- 8.5.9.1. South Korea: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.5.9.2. South Korea: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.5.9.3. South Korea: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.5.10. Molecular Diagnostics For Sexually Transmitted Diseases Market - Australia
- 8.5.10.1. Australia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.5.10.2. Australia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.5.10.3. Australia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.5.11. Molecular Diagnostics For Sexually Transmitted Diseases Market - Rest of Asia Pacific
- 8.5.11.1. Rest of Asia Pacific: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.5.11.2. Rest of Asia Pacific: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.5.11.3. Rest of Asia Pacific: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.6. Molecular Diagnostics For Sexually Transmitted Diseases Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.6.2. Middle East & Africa: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.6.3. Middle East & Africa: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.6.4. Molecular Diagnostics For Sexually Transmitted Diseases Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.6.4.2. Saudi Arabia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.6.4.3. Saudi Arabia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.6.5. Molecular Diagnostics For Sexually Transmitted Diseases Market - UAE
- 8.6.5.1. UAE: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.6.5.2. UAE: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.6.5.3. UAE: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.6.6. Molecular Diagnostics For Sexually Transmitted Diseases Market - Israel
- 8.6.6.1. Israel: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.6.6.2. Israel: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.6.6.3. Israel: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.6.7. Molecular Diagnostics For Sexually Transmitted Diseases Market - South Africa
- 8.6.7.1. South Africa: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.6.7.2. South Africa: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.6.7.3. South Africa: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.6.8. Molecular Diagnostics For Sexually Transmitted Diseases Market - Rest of Middle East & Africa
- 8.6.8.1. Rest of Middle East & Africa: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.6.8.2. Rest of Middle East & Africa: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.6.8.3. Rest of Middle East & Africa: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.7. Molecular Diagnostics For Sexually Transmitted Diseases Market - Latin America
- 8.7.1. Latin America: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.7.2. Latin America: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.7.3. Latin America: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.7.4. Molecular Diagnostics For Sexually Transmitted Diseases Market - Mexico
- 8.7.4.1. Mexico: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.7.4.2. Mexico: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.7.4.3. Mexico: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.7.5. Molecular Diagnostics For Sexually Transmitted Diseases Market - Brazil
- 8.7.5.1. Brazil: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.7.5.2. Brazil: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.7.5.3. Brazil: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.7.6. Molecular Diagnostics For Sexually Transmitted Diseases Market - Argentina
- 8.7.6.1. Argentina: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.7.6.2. Argentina: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.7.6.3. Argentina: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
- 8.7.7. Molecular Diagnostics For Sexually Transmitted Diseases Market - Rest of Latin America
- 8.7.7.1. Rest of Latin America: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
- 8.7.7.2. Rest of Latin America: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
- 8.7.7.3. Rest of Latin America: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. Abbott Laboratories
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Becton, Dickinson and Company (BD)
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. bioMerieux SA
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. DiaSorin S.p. A.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. F. Hoffmann-La Roche AG (Roche Diagnostics)
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Hologic Inc.
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. QIAGEN N.V.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. QuidelOrtho Corporation
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Seegene Inc.
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Siemens Healthineers AG
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. Thermo Fisher Scientific Inc.
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
샘플 요청 목록